Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Discontinuation of A-dopamine in Parkinson's Disease (DIVE-FOLLOW UP)
NCT07214285Phase 2Completed
- Sponsor
- CHU de Lille
- Start
- Oct 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
A Phase 2 trial of A-dopamine in Parkinson's disease (PD), sponsored by CHU de Lille. Started Oct 2025; status: completed.
02
Drugs
A-dopamine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07214285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07214285.